Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
207137-56-2
Molecular formula
Not available
Molecular weight
Not available
Drug class
Recombinant human interferon gamma (IFN-γ)immunomodulatory cytokine biologic
Mechanism of action
Binds the interferon-gamma receptor and activates JAK1/JAK2-STAT1 signalling, inducing interferon-responsive genes and enhancing macrophage activation and antigen presentation.
Indications / reported uses
Potential use in chronic granulomatous disease or other immune disorders depends on the specific interferon gamma product; binetrakin itself has no independently confirmed current marketing authorisation indication in the reviewed sources
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Binetrakin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Binetrakin Permitted Daily Exposure (PDE) report (the Binetrakin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Binetrakin Occupational Exposure Limit (OEL) report (the Binetrakin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.